Latest news with #FinanceIntroductiontoTechnicalAnalysis
Time of India
3 hours ago
- Business
- Time of India
Medical device firms sound the alarm over new steel standards
Confusion over the ministry of steel 's latest mandate could fuel shortages of surgical blades, needles, endoscopes and other medical products in the coming days, industry executives said. They said they were unable to follow the rules recently mandated by the ministry of steel saying raw material used in the manufacture of finished and semi-finished steel products must comply with Indian standards. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Earlier, foreign suppliers only needed BIS certification for finished steel products. Under the new rule, materials like hot rolled steel, ingots manufactured by other countries for Indian buyers will have to get BIS certification. The manufacturers have written to the ministry of steel seeking exemption for the import of stainless steel capillary without BIS certification. Several manufacturers ET spoke to said they have to rely on imports for certain steel pipes, tubes, steel strips, steel capillary tubes as the annual quantity is less and it is not commercially feasible for the vendor to proceed with BIS certification for these low quantities. For example, Hindustan Syringes & Medical devices , the leading maker of disposable and auto disposable syringes, is dependent on a Korean supplier for a specialised stainless steel capillary tube. "This is a low volume material hence making the BIS certification process is not feasible both economically and operationally. We have therefore requested the ministry of steel for exemption of the BIS requirement for the import," said Rajiv Nath, MD, HMD. Live Events The Association of Indian Medical Device Industry (AiMeD), a lobby group, has written to the ministry saying the healthcare system may face disruption as they are unable to import necessary stainless steel. "Despite efforts to source stainless-steel strip from local manufacturers such as Tata Steel , Jindal, BSL , Anil Metal, Stelco , and Mecon Limited, the required specification for manufacturing SS capillary tubing is not available in India as it is not sustainable or economical to produce small batches of tubing," the letter said. ET has seen a copy of the letter. "Manufacturing medical devices to global standards requires this specific stainless steel. Without it, the production, product quality, and delivery commitments, especially for exports, are at risk,"the letter said.
Time of India
5 hours ago
- Business
- Time of India
NSA Ajit Doval calls on Russian President Vladimir Putin
National Security Advisor Ajit Doval called on Russian President Vladimir Putin at the Kremlin on Thursday, the Kremlin press service said. A video clip shared by it showed Doval shaking hands with Putin before holding the talks. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Earlier, Doval held talks with Russian Security Council Secretary Sergey Shoigu. Doval arrived here on Wednesday to hold crucial talks on bilateral energy and defence ties and to prepare the ground for President Putin's visit to India later this year. His visit commenced on a day when US President Donald Trump issued an executive order slapping an additional 25 per cent tariff on Indian goods as a penalty for buying Russian oil, doubling it to 50 per cent.
Time of India
12 hours ago
- Business
- Time of India
Have money to deploy today? Put it in pharma funds, says Sandeep Tandon
Sandeep Tandon , CIO, Quant Mutual Fund , expresses strong confidence in India's decoupling process, highlighting Asia-centric emerging markets ' advantageous position over developed economies, evidenced by currency movements. He identifies the pharmaceutical sector as a prime beneficiary in the current economic climate. Tandon advocates for investing in pharma funds , deeming it a highly promising and straightforward investment strategy. I just want to pick up on the US indicators that you say could be headed for a deeper correction. In that sense, do you think that in the interim, India is decoupled right now or if they fall, will we fall too? Sandeep Tandon: A few months back also, we talked about the decoupling process beginning. In fact, in March we wrote about India decoupling. I will not say up to a large extent, but up to a small extent, the decoupling process has begun. If anything starts, it is a few years and a few quarters' process, and not going to happen overnight. So, purely on our macro understanding and our behaviour thesis, what we have built in last many years, we are confident that India decoupling process has already begun and not only India, also the emerging market, particularly Asia-centric emerging market is in a far better situation than the developed economies or the developed market and that trend is quite visible in the currency movement also. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How to Trade ETH/USD Without Holding Ether IC Markets Learn More Undo The whole world in January had written off emerging markets and talked about how the US will go and exactly the reverse happened. I am not saying you should take a contrarian call, but that was the thought process. People thought that Asian market currencies or the emerging market currencies would collapse significantly. Yes, they corrected and if you really ask me, either we have already seen the worst of rupee or we might be seeing very soon, but we are in the fag end of that also. In fact, from a longer-term perspective, the probability that 2025 will be remembered as a long-term top for the USD-INR and the Indian rupee should appreciate over the next five to six years and that is the clear message. If I have to do a reverse calculation and try to interpret it, if the rupee is going to get stronger over a period of five-six years, then obviously it is a clear indication the Indian market also should be doing very well. I want to address some sectors as well. You have a great understanding about the pharma sector. For now, they are exempt from tariffs. But there is all that noise that eventually it is going to be 250% tariffs. What is the practicality of it and for Indian investors, do you now make that disconnect and look at India-focused pharma companies as opposed to the ones which manufacture for the US? Sandeep Tandon: Let us sit down and analyse it all rationally and I am always surprised to see even the best of the analysts get carried away in this narrative getting built about that 250%. Let us understand the US compression. If you recollect, Trump has been threatening for a while, but if you really sit down and analyse, he has been targeting innovators, not generics. The point which he is trying to make is a lot of companies, which are US-centric but manufacture their product in Europe and have huge 50% to 80% or 90% margin when selling in the US. They understand there is a very large margin they are making and that is something they are talking about. A lot of people read it as, at least from the R&D perspective, the budget will go down. So, that is a secondary impact or tertiary impact that can happen. But their focus is on innovators and this time also, he was not able to do anything. Live Events You Might Also Like: Buy the dip and go for India-centric portfolio; US market more likely to correct sharply than India: Sandeep Tandon Despite making noise, ultimately he has a written letter to bring down the prices. Now, let us understand the larger this is. Does the US have any other source of buying generics or pharmaceuticals? India is the biggest supplier of generics and if innovators are penalised for whatever reason, money or people will shift towards generics and Indian generics are 70% to 90% cheaper as compared to comparative formulation in the US itself. So, the US or Mr Trump does not have too many options. See, you can defer buying a car for two years. You can defer buying garments or clothes for, let us say for six months or eight months, but you cannot defer buying medicine even for next two hours. That is the compulsion he has. So, we have to understand what is the objective? Yes, he is making noise. But he does not have a choice. If you want to source somewhere and set up manufacturing in the US, it takes three to five years to build a capacity and even then the US FD approval nowadays takes around 12 to 15 months, even 18 months. A lot of plants are still waiting for US approval. Within the US they are not able to devote time, their bandwidth is also limited. So, I do not think anything would happen in the pharma space in a hurry and Indian generics are in a very comfortable position and some of the companies like Lupin have manufacturing facilities in the US. Aurobindo is one of the large players and has two manufacturing facilities. They have recently acquired a third one. So, we have to identify all the generic companies, all the pharma companies that have bases in the US or other countries. If they are based in the US, that will give them comfort psychologically if something can drastically change and they can easily export or manufacture there. If you ask me, one single thesis in the current context is the beneficiary in absolute terms and relative terms is pharma. If you ask me where I should put my money if I have to deploy today, then I say put money in pharma funds. This is absolutely no-brainer trade. You Might Also Like: Prefer TVS Motors and Eicher to Bajaj Auto; Trump tariffs a big sword over market: Dipan Mehta
Time of India
a day ago
- Business
- Time of India
AppLovin stock spikes 4% on explosive Q2 earnings—can 77% revenue growth fuel its AI ad-tech dominance?
AppLovin posts blockbuster Q2 2025 results with massive 77% revenue spike- AppLovin is making serious waves in the tech and advertising space once again, delivering an eye-popping 77% year-over-year revenue jump in Q2 2025. The ad-tech powerhouse reported $1.259 billion in quarterly revenue—crushing Wall Street's expectations of around $1.22 billion. This strong performance not only shows the company's sharp pivot toward AI-powered advertising is paying off but also reinforces investor confidence, even as it sheds its gaming app division. AI ad-tech leads profitability surge with 99% YoY jump in EBITDA Adjusted EBITDA for Q2 came in at a staggering $1.018 billion, marking a 99% increase from the same period last year and surpassing analyst forecasts. This translates into a margin close to 81%, underscoring AppLovin's ability to scale profits through automation and AI optimization across its ad network. The company's strategic shift to focus purely on ad-tech seems to be fueling hyper-efficiency and robust margins. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Stock Movement : Intraday Surge : Up around 3–4% After-Hours Dip : Down ~2.2% Due to concerns post-apps division divestiture Current Price : ~$390.80 52-Week Range : ~$66 to ~$525 Technical Buy Point : Near $429 Identified as : Breakout stock by IBD Technical Rating : 'Strong Buy' across platforms Net income skyrockets 164% as AppLovin beats Wall Street expectations The bottom line was just as impressive: AppLovin reported net income of $820 million—up 164% year-over-year—with $772 million attributed to continuing operations. Earnings per share (EPS) hit $2.39, blowing past the $1.95 consensus by a wide margin of nearly $0.44. These results clearly reflect the company's sharp execution in monetizing its platform at scale, without the overhead of its former gaming business. Q3 2025 guidance signals more growth ahead for AppLovin Looking forward, AppLovin projects Q3 2025 revenue between $1.32 billion and $1.34 billion, coupled with adjusted EBITDA guidance of $1.07 billion to $1.09 billion. That means margins are expected to remain around 81%, a strong indicator that its high-growth ad-tech model remains on a firm upward trajectory. This guidance continues to paint a promising picture for sustained growth as demand for programmatic advertising and AI ad solutions accelerates. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The Fastest Way to Overcome Knee Pain and Swelling Wellnee Undo Despite stellar earnings, stock dips slightly in after-hours trading Interestingly, even after the beat across all major metrics and bullish forward guidance, AppLovin's stock dipped roughly 2.2% in after-hours trading. Analysts suggest this may reflect cautious sentiment about the company's recent divestiture from its gaming app division, as some investors assess the long-term impact of the pivot to an ad-tech-only model. However, the pullback appears to be more a short-term reaction than a reflection of fundamentals. Wall Street analysts remain bullish with up to 40% upside forecast Despite the minor after-hours dip, analysts remain strongly bullish. The median 12-month price target sits at $485, while Wedbush and Jefferies have issued even more optimistic projections at $620 and $530, respectively. Based on AppLovin's current trading price of approximately $390.80, this implies an upside potential of 20% to 40%. The stock also continues to attract institutional backing, reinforcing confidence in its long-term potential. AppLovin ranks among top mutual fund holdings alongside Nvidia and Meta Institutional investors are clearly impressed. AppLovin has become one of the top mutual fund picks in 2025, pulling in around $1.44 billion in inflows. That places it just behind giants like Nvidia and Meta. As funds continue to chase AI-driven growth stories, AppLovin's transformation into a focused ad-tech leader is cementing its place as a serious player in the AI economy. Key Financial Results : Revenue : $1.259 billion (Up 77% YoY) Beat consensus estimate of ~$1.22 billion Adjusted EBITDA : $1.018 billion (Up 99% YoY) Surpassed analyst expectations Margin ~81% Net Income : $820 million total $772 million from continuing operations (Up 164% YoY) Earnings Per Share (EPS) : $2.39 Beat by ~$0.44 (vs. $1.95 expected) Strong technical indicators show bullish momentum for AppLovin stock From a technical perspective, AppLovin has been flagged as a breakout stock by Investor's Business Daily, with a potential buy point near $429. The current price of around $390.80 puts it in a favorable consolidation pattern, suggesting more room for gains. Moving averages and technical charts also indicate a 'Strong Buy' rating across multiple trading platforms. Live Events AppLovin's strategic pivot to AI ad-tech continues to deliver results In summary, AppLovin's Q2 2025 performance reflects the strength of its AI-powered ad-tech engine. The decision to move away from its gaming apps and double down on AI advertising seems to be paying off big. With stellar revenue growth, soaring profits, high institutional interest, and upbeat guidance, the company is clearly positioning itself as a top-tier AI ad-tech player. While some investors may remain cautious in the short term, the long-term fundamentals appear strong. AppLovin's strategic clarity, strong cash flows, and market-leading margins make it a stock to watch as the AI advertising revolution continues to reshape the digital economy. FAQs: Q1: What drove AppLovin's 77% revenue growth in Q2 2025? AppLovin's AI-powered ad-tech engine fueled massive growth and strong platform demand. Q2: Why is AppLovin stock seen as a breakout investment in 2025? Analysts cite strong earnings, high margins, and bullish AI ad-tech strategy.
Time of India
a day ago
- Politics
- Time of India
Donald Trump is a resident of Bihar? Prankster files for certificate in US President's name — here's what happened
A prankster in Bihar's Samastipur district tried to pull a fast one by applying for a residence certificate under the name "Donald Trump," claiming the former US president was a local resident. However, the district administration wasn't amused. It swiftly rejected the application and has now ordered an FIR to track down the mischief-maker behind the stunt. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program In a statement, officials said the online application was submitted on July 29, but the revenue department rejected it on August 4. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Rates Undo The application claimed that Donald Trump, complete with a photo, was a resident of Hasanpur village. The prankster appeared to have done some homework too — listing Frederick Christ Trump and Mary Anne MacLeod as the applicant's parents, the actual names of the former US president's father and mother. "It appears there is a diabolical attempt to negatively impact the special intensive revision of electoral rolls which is underway as per the instructions of the Election Commission," the administration stated. Live Events Notably, this is the fourth incident of its kind reported in the state since the mammoth exercise by the EC began in June. Recently, applications were received in rural Patna and Nawada in the name of canines named 'dog babu', and 'dogesh babu', respectively. In East Champaran district, an application was received in the name of 'Sonalika tractor', with the photograph of a Bhojpuri actress. Applications in all the aforementioned cases have been rejected, and FIRs were lodged at the police stations concerned. The Samastipur administration also said, "In view of the seriousness of the offence, a case has been lodged at the Cyber police station, Samastipur, for appropriate investigation and action." Senior Congress leader Randeep Singh Surjewala shared a news clip that said "certificate has been issued" in favour of the application. Surjewala said, "This is the biggest proof that electoral roll revision in Bihar is a fraud, aimed at stealing votes. The Congress and Rahul Gandhi are fighting to thwart this design. Keeping quiet in such a situation is a crime. Let us all raise our voices and become watchdogs of democracy." The Samastipur administration found itself explaining to Surjewala, "The certificate has never been issued. Somebody has deliberately made such an application and it was rejected during scrutiny. An FIR has also been lodged. The guilty will not be spared."
